HS3ST2 modulates breast cancer cell invasiveness via MAP kinase-and Tcf4 (Tcf7l2)-dependent regulation of protease and cadherin expression

International Journal of Cancer

Volumn 135, Issue 11, 2014, Pages 2579-2592

  Kumar, Archana Vijaya ^a   Gassar, Ezeddin Salem ^a,b   Spillmann, Dorothe ^c   Stock, Christian ^d   Sen, Yin Ping ^e   Zhang, Ting ^e   Van Kuppevelt, Toin H ^f   Hulsewig, Carolin ^a   Kozlowski, Eliene O ^g   Pavao, Mauro S G ^g   Ibrahim, Sherif A ^h   Poeter, Michaela ^d   Rescher, Ursula ^d   Kiesel, Ludwig ^a   Koduru, Suresh ⁱ   Yip, George W ^e   Gotte, Martin ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF BENGHAZI   (Libyan Arab Jamahiriya)

^c UPPSALA UNIVERSITY   (Sweden)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^h CAIRO UNIVERSITY   (Egypt)

ⁱ UNIVERSITY OF HYDERABAD   (India)

Author keywords

Cadherin; Chemosensitivity; Glycosaminoglycan; Heparan sulfate; Invasiveness; Metastasis; Signal transduction

Indexed keywords

ADAM PROTEIN; ADAMTS1 PROTEIN; ADAMTS17 PROTEIN; ADAMTS6 PROTEIN; ANNEXIN; ANNEXIN A10; CADHERIN; CADHERIN 11; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CISPLATIN; COLLAGENASE 3; DOXORUBICIN; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; GELATINASE B; HEPARAN SULFATE 3 O SULFOTRANSFERASE 2; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 19; MATRIX METALLOPROTEINASE 28; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEINASE; SULFOTRANSFERASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TCF4; UNCLASSIFIED DRUG; UVOMORULIN; ANTINEOPLASTIC AGENT; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; BETA CATENIN; GLYCOSAMINOGLYCAN; HEPARAN-SULFATE 2-SULFOTRANSFERASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; TCF4 PROTEIN, HUMAN; TRANSCRIPTION FACTOR 7 LIKE 2;

ACIDIFICATION; ARTICLE; BREAST CANCER CELL LINE; CANCER RESISTANCE; CELL INVASION; CELL PH; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION REGULATION; HS3ST2 GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; WESTERN BLOTTING; BREAST NEOPLASMS; CELL ADHESION; CELL MOTION; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; ENZYME IMMUNOASSAY; FEMALE; FLUORESCENCE MICROSCOPY; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; TUMOR INVASION; VASCULAR ENDOTHELIUM;

ANTINEOPLASTIC AGENTS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BETA CATENIN; BLOTTING, WESTERN; BREAST NEOPLASMS; CADHERINS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; ENDOTHELIUM, VASCULAR; FEMALE; GLYCOSAMINOGLYCANS; HUMANS; IMMUNOENZYME TECHNIQUES; MICROSCOPY, FLUORESCENCE; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM INVASIVENESS; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SULFOTRANSFERASES; TRANSCRIPTION FACTOR 7-LIKE 2 PROTEIN; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 84910110007     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28921     Document Type: Article

References (50)

1. Yip GW, Smollich M, Gotte M. Therapeutic value of glycosaminoglycans in cancer. Mol Cancer Ther 2006;5:2139-48.
2. Afratis N, Gialeli C, Nikitovic D, et al. Glycosaminoglycans: key players in cancer cell biology and treatment. FEBS J 2012;279:1177-97.
3. Nikolova V, Koo CY, Ibrahim SA, et al. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis 2009;30:397-407.
4. Baeg GH, Lin X, Khare N, et al. Heparan sulfate proteoglycans are critical for the organization of the extracellular distribution of Wingless. Development 2001;128:87-94.
5. DeleheddeM,Deudon E, Boilly B, et al.Heparan sulfate proteoglycans play a dual role in regulating fibroblast growth factor-2mitogenic activity in human breast cancer cells. Exp Cell Res 1996;229:398-406.
6. Rapraeger AC, Krufka A, Olwin BB. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 1991;52:1705-8.
7. Goodger SJ, Robinson CJ, Murphy KJ, et al. Evidence that heparin saccharides promote FGF2 mitogenesis through two distinct mechanisms. J Biol Chem 2008;283:13001-8.
8. Jastrebova N, Vanwildemeersch M, Rapraeger AC, et al. Heparan sulfate-related oligosaccharides in ternary complex formation with fibroblast growth factors 1 and 2 and their receptors. J Biol Chem 2006;281:26884-92.
9. Gallagher JT. Multiprotein signalling complexes: regional assembly on heparan sulphate. Biochem Soc Trans 2006;34:438-41.
10. Liu BY, Kim YC, Leatherberry V, et al. Mammary gland development requires syndecan-1 to create a beta-catenin/TCF-responsive mammary epithelial subpopulation. Oncogene 2003;22:9243-53.
11. Hassan H, Greve B, Pavao MS, et al. Syndecan-1 modulates b-integrin-dependent and interleukin-6-dependent functions in breast cancer cell adhesion, migration, and resistance to irradiation. FEBS J 2013;280:2216-27.
12. Beauvais DM, Ell BJ, McWhorter AR, et al. Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. J Exp Med 2009;206:691-705.
13. Thacker BE, Xu D, Lawrence R, et al. Heparan sulfate 3-O-sulfation: a rare modification in search of a function. Matrix Biol 2013 Dec 19. pii: S0945-053X(13)00169-8. doi: 10.1016/j.matbio.2013.12.001.
14. Shworak NW, Liu J, Petros LM, et al. Multiple isoforms of heparan sulfate D-glucosaminyl 3-Osulfotransferase. Isolation, characterization, and expression of human cdnas and identification of distinct genomic loci. J Biol Chem 1999;274:5170-84.
15. Miyamoto K, Asada K, Fukutomi T, et al. Methylation-associated silencing of heparin sulfate Dglucosaminyl 3-O-sulfotransferase-2 (3-OST-2) in human breast, colon, lung and pancreatic cancers. Oncogene 2003;22:274-80.
16. Mahapatra S, Klee EW, Young CY, et al. Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res 2012;18:2882-95.
17. Montesano R, Pepper MS, Mohle-Steinlein U, et al. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell 1990;62:435-45.
18. Gotte M, Mohr C, Koo CY, et al. miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness. Oncogene 2010;29:6569-80.
19. Ledin J, Staatz W, Li JP, et al. Heparan sulfate structure in mice with genetically modified heparan sulfate production. J Biol Chem 2004;279: 42732-41.
20. Ten Dam GB, Kurup S, van de Westerlo EM, et al. 3-O-sulfated oligosaccharide structures are recognized by anti-heparan sulfate antibody HS4C3. J Biol Chem 2006;281:4654-62.
21. Dordick RS, Brierley GP, Garlid KD. On the mechanism of A23187-induced potassium efflux in rat liver mitochondria. J Biol Chem 1980;255: 10299-305.
22. Kirschberger S, Busche R, Engelhardt WV. Surface pH at the basolateral membrane of the caecal mucosa of guinea pig. J Membr Biol 1999;169: 111-22.
23. Kovbasnjuk ON, Spring KR. The apical membrane glycocalyx of MDCK cells. J Membr Biol 2000;176:19-29.
24. Vanhoutte D, Schellings MW, Gotte M, et al. Increased expression of syndecan-1 protects against cardiac dilatation and dysfunction after myocardial infarction. Circulation 2007;115:475-82.
25. Kozlowski EO, Pavao MS, Borsig L. Ascidian dermatan sulfates attenuate metastasis, inflammation and thrombosis by inhibition of P-selectin. J Thromb Haemost 2011;9:1807-15.
26. Hoshino R, Chatani Y, Yamori T, et al. Constitutive activation of the 41-/43-kDa mitogenactivated protein kinase pathway in human tumors. Oncogene 1999;18:813-22.
27. Krueger JS, Keshamouni VG, Atanaskova N, et al. Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion. Oncogene 2011; 20:4209-18.
28. Knauper V, Will H, Lopez-Otin C, et al. Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J Biol Chem 1996;271:17124-31.
29. Kaushal GP, Xiong X, Athota AB, et al. Syndecan-1 expression suppresses the level of myeloma matrix metalloproteinase-9. Br J Haematol 1999; 104:365-73.
30. Gao G, Plaas A, Thompson VP, et al. ADAMTS4 (aggrecanase-1) activation on the cell surface involves C-terminal cleavage by glycosylphosphatidyl inositol-anchored membrane type 4-matrix metalloproteinase and binding of the activated proteinase to chondroitin sulfate and heparan sulfate on syndecan-1. J Biol Chem 2004;279:10042-51.
31. Christofori G, Semb H. The role of the celladhesion molecule E-cadherin as a tumoursuppressor gene. Trends Biochem Sci 1999;24:73-6.
32. Pishvaian MJ, Feltes CM, Thompson P, et al. Cadherin-11 is expressed in invasive breast cancer cell lines. Cancer Res 1999;59:947-52.
33. Farina AK, Bong YS, Feltes CM, et al. Post-transcriptional regulation of cadherin-11 expression by GSK-3 and beta-catenin in prostate and breast cancer cells. PLoS One 2009;4:e4797.
34. Liu J, Di G, Wu CT, et al. CEACAM1 inhibits cell-matrix adhesion and promotes cell migration through regulating the expression of N-cadherin. Biochem Biophys Res Commun 2013;430:598-603.
35. Ibrahim SA, Hassan H, Vilardo L, et al. Syndecan-1 (CD138) modulates triple-negative breast cancer stem cell properties via regulation of LRP-6 and IL-6-mediated STAT3 signaling. PLoS One 2013;8:e85737.
36. Hatzis P, van der Flier LG, van Driel MA, et al. Genome-wide pattern of TCF7L2/TCF4 chromatin occupancy in colorectal cancer cells. Mol Cell Biol 2008;28:2732-44.
37. Munksgaard PP, Mansilla F, Brems Eskildsen AS, et al. Low ANXA10 expression is associated with disease aggressiveness in bladder cancer. Br J Cancer 2011;105:1379-87.
38. Hsieh MJ, Chen KS, Chiou HL, et al. Carbonic anhydrase XII promotes invasion and migration ability of MDA-MB-231 breast cancer cells through the p38 MAPK pathway. Eur J Cell Biol 2010;89:598-606.
39. Huang Y, Anderle P, Bussey KJ, et al. Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 2004;64:4294-301.
40. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011;278:16-27.
41. Meloche S, Pouysségur J. The ERK1/2 mitogenactivated protein kinase pathway as a master regulator of the G1-to S-phase transition. Oncogene 2007;26:3227-39.
42. Reddy KB, Krueger JS, Kondapaka SB, et al. Mitogen-activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP-9) in breast epithelial cells. Int J Cancer 1999;82: 268-73.
43. De Toni F, Racaud-Sultan C, Chicanne G, et al. A crosstalk between the Wnt and the adhesiondependent pathways governs the chemosensitivity of acute myeloid leukemia. Oncogene 2006;25: 3113-22.
44. Nieman MT, Prudoff RS, Johnson KR, et al. Ncadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol 1999;147:631-44.
45. Larsen AK, Escargueil AE, Skladanowski A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther 2000;85:217-29.
46. Hlavata I, Mohelnikova-Duchonova B, Vaclavikova R, et al. The role of ABC transporters in progression and clinical outcome of colorectal cancer. Mutagenesis 2012;27:187-96.
47. Stock C, Schwab A. Protons make tumor cells move like clockwork. Pflugers Arch 2009;458:981-92.
48. Gerweck LE, Vijayappa S, Kozin S. Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. Mol Cancer Ther 2006;5: 1275-9.
49. Karamanos NK, Tzanakakis GN. Glycosaminoglycans: from "cellular glue" to novel therapeutical agents. Curr Opin Pharmacol 2012;12:220-2.
50. Weyers A, Yang B, Yoon DS, et al. A structural analysis of glycosaminoglycans from lethal and nonlethal breast cancer tissues: toward a novel class of theragnostics for personalized medicine in oncology? OMICS 2012;16:79-89.